The 2008 Arden House European conference is a three-day conference presented by the Royal Pharmaceutical Society of Great Britain (RPSGB), the Academy of Pharmaceutical Sciences (APS) and the American Association of Pharmaceutical Scientists (AAPS).

The drive for signifi cant step change in the industry’s manufacturing performance continues to highlight the limited understanding and critical importance of the physical characteristics of both APIs and excipients, and their process interactions, on manufacturing and ultimately clinical performance. The introduction of ICH guidelines Q8 and Q10 indicate that quality cannot be tested into products and provide the necessary driver to ensure processes are under control and the concept of “quality by design” will become commonplace in the industry.

There is now no doubt that particle and powder technologies will play an increasingly key role in bridging the current process understanding and performance gap that exists between API and Drug Product Manufacture and the even more complex processing requirements of combination presentations predicted in the future.

Please refer to conference programme for more details